Higher CD9 positive EV were evident in in prostate cancer patients compared to men diagnosed with BPH (Figure 4A), while measurement of CD63 positive EV and PSA did not show significant differences between the cohorts (Figure 4B and 4C). Here, CD63 is linked to prostate cancer.